Quant Biomarkers AG is a Basel-based Swiss company developing clinically actionable biomarker solutions across the cardio-kidney-metabolic (CKM) disease spectrum, enabling earlier diagnosis, treatment monitoring, and disease progression assessment. The first product developed by Quant Biomarkers AG is RenoRisk™, a proprietary multi-analyte urinary biomarker signature for early kidney injury detection.

Why It Matters

• >40% of the world population, e.g. those with cardiovascular or metabolic indications, are at risk of renal impairment
• Over 850 million people worldwide are already affected by CKD
• ~90% remain undiagnosed until significant kidney function is already lost
• Current standards (eGFR, UACR) detect late functional decline, not early tissue injury

This delay leads to missed treatment opportunities and escalating mortality due to complications and end-stage renal care costs.

Our Solution – RenoRisk™

RenoRisk™ detects early kidney injury rather than late functional loss.

It is:

• Highly conserved across species and nephropathies
• Validated across human, animal, and pediatric cohorts
• Designed for both clinical diagnostics and pharma/biotech applications
• Protected by global patents pending

Dual Market Focus

Quant Biomarkers operates a two-engine business model:

• Pharma & Biotech (near-term):
  Research-use diagnostics, patient stratification, and trial surrogate endpoints
• Clinical Diagnostics (mid-term):
  Single-lab services, regulated test kits, and point-of-care solutions

Scientific & Institutional Backing

The company is supported by leading nephrology experts, Swiss and international academic centers, and has secured highly competitive non-dilutive Innosuisse funding, underscoring both scientific credibility and commercial relevance.